Amphastar Pharmaceuticals (AMPH) Scheduled to Post Earnings on Wednesday

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) will announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.73 per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts' consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. On average, analysts expect Amphastar Pharmaceuticals to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Amphastar Pharmaceuticals Trading Up 2.0 %

Shares of NASDAQ:AMPH traded up $0.83 during midday trading on Wednesday, reaching $42.08. The company had a trading volume of 434,952 shares, compared to its average volume of 448,252. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.70 and a current ratio of 2.17. Amphastar Pharmaceuticals has a 1-year low of $35.93 and a 1-year high of $67.66. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of 16.31, a price-to-earnings-growth ratio of 1.00 and a beta of 0.84. The company has a fifty day simple moving average of $43.89 and a two-hundred day simple moving average of $50.82.

Insider Transactions at Amphastar Pharmaceuticals

In other news, Director Michael A. Zasloff sold 12,500 shares of the firm's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the sale, the director now directly owns 21,326 shares of the company's stock, valued at approximately $1,006,160.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Michael A. Zasloff sold 12,500 shares of the firm's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the sale, the director now directly owns 21,326 shares of the company's stock, valued at approximately $1,006,160.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Floyd F. Petersen sold 500 shares of the firm's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $53.10, for a total value of $26,550.00. Following the sale, the director now directly owns 80,333 shares of the company's stock, valued at $4,265,682.30. The disclosure for this sale can be found here. Insiders sold 14,000 shares of company stock valued at $660,860 in the last three months. Corporate insiders own 27.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AMPH. JPMorgan Chase & Co. began coverage on Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an "overweight" rating and a $60.00 price objective for the company. StockNews.com lowered Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, February 29th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $66.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.